Aurobindo Pharma Q4 FY23 PAT up at Rs. 506 Cr
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
8th Edition of the event to promote India as a manufacturing hub of quality medical products in the Pharmaceutical and Medical Devices Sector
The facility will have a capacity to manufacture upto 3 million tubes monthly
The addition of these two hospitals will provide increased access to specialized pediatric and perinatal care services in the geography
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
Pandemic was the opportunity for Ayush to develop their science and Ayush did it by developing Ayush 64, etc
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
Subscribe To Our Newsletter & Stay Updated